Treatment Landscape and Unmet Needs in Advanced Gastric Cancers
Panelists discuss how advanced gastric cancer treatments currently include surgery, chemotherapy (primarily platinum/fluoropyrimidine combinations), targeted therapies (trastuzumab for HER2-positive disease, ramucirumab), and immunotherapy (pembrolizumab and nivolumab in select patients). Despite these options, major unmet needs persist, with low survival rates, lack of predictive biomarkers beyond HER2, limited effective treatments after first-line therapy, poor response rates to immunotherapy, and high treatment toxicity affecting quality of life. Many patients also present with late-stage disease due to delayed diagnosis.
Now Viewing
EP: 1.Treatment Landscape and Unmet Needs in Advanced Gastric Cancers
EP: 2.CheckMate649 5-Year Follow-Up, Study Design, and Efficacy Results
EP: 3.Evaluating Long-Term Outcomes and Personalized Treatment Strategies in Advanced Gastrointestinal Cancers
EP: 4.Assessing the Long-Term Safety and Efficacy of Nivolumab Plus Chemotherapy for Broader Clinical Adoption in Advanced GI Cancers
EP: 5.Balancing Treatment Intensity, Quality of Life, and Biomarker-Driven Approaches in Advanced GI Cancers
EP: 6.Advancing First-Line Treatment Strategies in Gastric and Esophageal Cancers
EP: 7.Key Takeaways and Future in Advanced Gastric Cancer Treatment
EP: 8.Updated Nivolumab Data Solidify Use in Advanced Gastric/GEJ/Esophageal Cancers
Video content above is prompted by the following:
- Briefly discuss the current treatment landscape for advanced gastric cancers.
- What are some unmet needs in this patient population?
Recent Videos
Related Content
